<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02714569</url>
  </required_header>
  <id_info>
    <org_study_id>16417</org_study_id>
    <secondary_id>I8Q-MC-GSEA</secondary_id>
    <nct_id>NCT02714569</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY3202328</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this two-part study is to evaluate the safety and tolerability of the study
      drug known as LY3202328 in healthy overweight participants in Part A, and those with
      dyslipidemia (abnormal blood fats) in Part B.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline up to 42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of LY3202328</measure>
    <time_frame>Baseline up to 42 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration time Curve (AUC) from Zero to Infinity of LY3202328</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-Time Curve (AUC tau) of LY3202328</measure>
    <time_frame>Baseline up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration (Tmax) of LY3202328</measure>
    <time_frame>Baseline up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting High-Density Lipoprotein Cholesterol (HDL-c)</measure>
    <time_frame>Baseline, up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Total Triglycerides</measure>
    <time_frame>Baseline, up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Total Cholesterol</measure>
    <time_frame>Baseline, up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Low-Density Lipoprotein Cholesterol (LDL-c)</measure>
    <time_frame>Baseline, up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simvastatin Cmax in LY3202328 Co-administration</measure>
    <time_frame>Baseline up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atorvastatin Cmax in LY3202328 Co-administration</measure>
    <time_frame>Baseline up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simvastatin AUC 0-24 in LY3202328 Co-administration</measure>
    <time_frame>Baseline up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atorvastatin AUC 0-24 in LY3202328 Co-administration</measure>
    <time_frame>Baseline up to 29 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Part A: LY3202328</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single ascending dose of LY3202328 orally, in 2 periods while fasting, and up to one period while fed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single ascending dose of placebo orally, in 1 period while fasting, and up to one period while fed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LY3202328</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A multiple ascending dose of LY3202328 at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A multiple ascending dose of placebo at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3202328</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part A: LY3202328</arm_group_label>
    <arm_group_label>Part B: LY3202328</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_label>Part B: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part B: LY3202328</arm_group_label>
    <arm_group_label>Part B: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part B: LY3202328</arm_group_label>
    <arm_group_label>Part B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be healthy, as determined by medical history and physical examination

          -  Male participants must agree to use a reliable method of birth control during the
             study and 3 months following the last dose of the investigational product

          -  Female participants must be between 40 and 70 years old, and either postmenopausal or
             with a hysterectomy, and not pregnant and not lactating

          -  Be on a stable diet and exercise regimen for greater than (&gt;) 3 months prior

          -  Have a body mass index (BMI) of 25.0 (Part A) or 27.0 (Part B) to 40.0 kilograms per
             meter squared

          -  Have fasting triglycerides (TG) between 150 and 499 milligrams per deciliter (mg/dL)
             (Part B only)

          -  Have a fasting low-density lipoprotein cholesterol (LDL-c) between 100 and 200 mg/dL
             (Part B only)

          -  Have estimated glomerular filtration rate greater than or equal to (≥) 60 milliliters
             per minute/1.73 meter squared with no proteinuria

          -  Be normotensive defined as supine systolic blood pressure (BP) less than or equal to
             (≤) 150 millimeters of mercury (mm Hg) and diastolic BP ≤ 100 mm Hg, without the use
             of any antihypertensive

        Exclusion Criteria:

          -  Are taking a statin, any proprotein convertase subtilisin/kexin type 9 (PCSK9)
             medications, or have started taking other TG lowering agents (for example, niacin,
             fish oils)

          -  Are currently enrolled in a clinical trial involving an investigational product or
             off-label use of a drug or device, or are concurrently enrolled in any other type of
             medical research, or have participated in a clinical trial involving an
             investigational product or non-approved use of a drug within the last 30 days or
             within 5 half-lives

          -  Have an abnormal electrocardiogram or corrected QT or are on antihypertensive
             treatment

          -  Have any current or prior history of significant cardiovascular disease

          -  Show evidence of hepatitis C virus (HCV), Hepatitis B or other chronic liver disease

          -  Have an alcohol intake that exceeds 7 units per week with no more than 3 units per
             day, or are unwilling to stop alcohol consumption for the duration of the study (1
             unit = 12 ounces or 360 mL of beer; 5 ounces or 150 mL of wine; 1.5 ounces or 45 mL of
             distilled spirits), or are a regular user of known drugs of abuse

          -  Have a history of untreated endocrine illness such as diabetes mellitus

          -  Have been on medications or supplements for weight loss within 3 months

          -  Have a history of active neuropsychiatric disease or on pharmacological therapy for
             such conditions (Part B, only)

          -  Show evidence of human immunodeficiency virus (HIV) infection

          -  Have been on medications that are known to inhibit cytochrome P450, family 3,
             subfamily A (CYP3A) or P-glycoprotein (P-gp), or regularly consume grapefruit

          -  Have donated blood of more than 500 mL within the last month

          -  Smoke &gt;10 cigarettes per day or are unwilling to follow smoking rules
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>06219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/dyslipidemia/GSEA#?postal=</url>
    <description>A Study of LY3202328 in Overweight Healthy Participants and in Participants With Dyslipidemia</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2016</study_first_submitted>
  <study_first_submitted_qc>March 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <last_update_submitted>March 10, 2017</last_update_submitted>
  <last_update_submitted_qc>March 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

